This finding is encouraging, as a phase Ib/IIa clinical trial of a combination of Carboplatin and the oral BET inhibitor PLX2853 to treat platinum-resistant ovarian cancers has recently been reported [41]. The gene discussed is DNER; the disease is ovarian carcinoma.